OneSkin raises $20M in Series A funding for skin longevity research



OneSkin, a biotechnology company focused on skin longevity, will use the $20 million Series A investment round to expand research and development of anti-aging skin care products. The investment round was led by Selva Ventures, with additional support from Unilever Ventures, Able Partners, and additional investors, including model and entrepreneur Camila Alves McConaughey and tech entrepreneur Kevin 

Advancing skin longevity science with OS-01 Peptide

Founded in 2016 by four Brazilian scientists, OneSkin specializes in anti-aging solutions targeting cellular aging processes. According to the company, the brand’s core ingredient, OS-01, is a patented peptide that “is the first peptide scientifically proven to reverse skin’s biological age by preventing the accumulation of senescent cells,” contributing to the visible signs of aging.

In a statement on the funding, OneSkin Co-Founder and CEO Dr. Carolina Oliveira said, “At OneSkin, we are excited to announce this new round of funding, which will further drive our mission to transform how we think about our skin, not only by optimizing our aesthetics using cutting-edge science, but also focusing on its functional role as our largest organ and the impact in our overall health and longevity.”

According to OneSkin, the funds will allow the company to increase its research capacity and expand its product offerings in the growing skin longevity sector.

Investment to support innovation and market expansion

The Series A funding is expected to support OneSkin in developing additional formulations and expanding its market reach. Dr. Alessandra Zonari, OneSkin’s Co-Founder and Chief Science Officer, commented in a press statement, “This investment will allow us to deepen our commitment to be the best in class in delivering efficacious peptides to modulate aging at the cellular level, ensuring that our science-backed solutions deliver measurable results in promoting healthier skin.”



Source link

About The Author

Scroll to Top